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Introduction
To update an existing and previously published eco-
nomic (micro-simulation model) in HIV (ARAMIS) to
reflect current treatment patterns and to evaluate the
cost-effectiveness of maraviroc (MVC) in France.
Materials and methods
A systematic literature review was carried out in
PubMed to identify all articles published in the past 5
years to provide new data to update the existing model.
A total of 1964 abstracts were identified on opportunis-
tic infections (OIs), health consequences (effects on
health over the longer term e.g. cancer), costs, quality of
life, adherence, resistance and efficacy of treatments. In
addition, current guidelines were identified and
reviewed. New data were included for OIs, costs, treat-
ments and LT health consequences. Treatments
focussed on maraviroc, etravirine (ETR) and raltegravir
(RAL) including optimised background therapy (OBT)
for treatment-experienced patients at the model’ss t a r t .
All relevant trials with these agents were identified, data
were extracted and used in a meta-analysis (results not
provided here) which provided relative efficacy data at
48 and 96 weeks. Treatment algorithms were updated
based on guidelines and expert opinion. Costs were at
the 2011 level based on official sources. There were
insufficient data on adherence to include this in the
model.
Results
The updated version of the ARAMIS model indicates
that MVC compared to RAL or ETR over a life time is
associated with more QALYs (a difference of 0.037 and
0.134 respectively) but higher total costs (a difference of
€1,439 and €4,766, respectively). The incremental cost
effectiveness ratio for MVC compared to RAL or ETR is
€39,300 and €35,700. Assuming a threshold of €50,000
MVC can be considered cost-effective compared to RAL
and ETR. Life expectancy with MVC was similar to RAL
(0.37 month difference) and higher than ETR (1.58
months difference).
Conclusion
MVC is a cost-effective treatment option for CCR5 tro-
pic treatment-experienced patients in France.
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